G
Gerald F. Watts
Researcher at University of Western Australia
Publications - 961
Citations - 52245
Gerald F. Watts is an academic researcher from University of Western Australia. The author has contributed to research in topics: Lipoprotein & Apolipoprotein B. The author has an hindex of 100, co-authored 889 publications receiving 43807 citations. Previous affiliations of Gerald F. Watts include Glasgow Royal Infirmary & King's College London.
Papers
More filters
Journal ArticleDOI
New Horizons: Revival of Lipoprotein (a) as a risk factor for cardiovascular disease.
TL;DR: Clinical practice guidelines have been developed to address gaps in care of high Lp(a), but full implementation awaits the findings of clinical outcome trials using RNA-directed therapies currently underway.
Journal ArticleDOI
Unravelling lipoprotein metabolism with stable isotopes: tracing the flow
TL;DR: In this article, the authors defined the kinetic mechanisms of action of proprotein convertase subtilisin/kexin type 9 and angiopoietin-like 3 inhibitors on lipid and lipoprotein mechanism in dyslipidemic subjects.
Journal ArticleDOI
Comparison of Urinary Albumin, Retinol-Binding Protein and N-Acetyl β-Glucosaminidase as Predictors of Progression of Low Level Albuminuria in Diabetes
TL;DR: The ability of markers of tubular dysfunction to predict the development of microalbuminuria has not been described previously, but may have important implications in identifying at risk patients and in predicting the progression of low level albuminuria.
Journal ArticleDOI
A novel missense SMPD1 gene mutation, T460P, and clinical findings in a patient with Niemann-Pick disease type B presenting to a lipid disorders clinic
Yael J. Grasko,Amanda J. Hooper,Amanda J. Hooper,John R. Burnett,John R. Burnett,Gerald F. Watts,Gerald F. Watts +6 more
TL;DR: The clinical findings of a case of NPD-B with mixed hyperlipidaemia, compound heterozygous for the SMPD1 ΔR608 mutation and a novel mutation, T460P are described.
Journal Article
An audit of pharmacists’ knowledge of familial hypercholesterolaemia: Implications for community healthcare
TL;DR: An adequate remuneration model may be required to encourage pharmacists to conduct point-of-care lipid testing and patient education, although there are deficiencies in the knowledge and awareness of FH which would require further education.